Deshmukh AA, Lin YY, Damgacioglu H, et al. Recent and projected incidence trends and risk of anal cancer among people with HIV in North America. JNCI J Natl Cancer Inst. 2024;116(9):1450–8. https://doi.org/10.1093/jnci/djae096.

Article  PubMed  PubMed Central  Google Scholar 

Jhaveri K, Modi K, Sarfraz H, et al. 20-year incidence trends of anal squamous cell carcinoma. J Clin Oncol. 2023;41(16suppl):e15503–15503. https://doi.org/10.1200/JCO.2023.41.16_suppl.e15503.

Article  Google Scholar 

Osborne MC, Maykel J, Johnson EK, Steele SR. Anal squamous cell carcinoma: An evolution in disease and management. World J Gastroenterol WJG. 2014;20(36):13052–9. https://doi.org/10.3748/wjg.v20.i36.13052.

Article  PubMed  PubMed Central  Google Scholar 

Rao S, Sclafani F, Eng C, et al. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol. 2020;38(22):2510–8. https://doi.org/10.1200/JCO.19.03266.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353–65. https://doi.org/10.1016/S1470-2045(20)30445-9.

Article  CAS  PubMed  Google Scholar 

Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer. 2012;12(8):553–63. https://doi.org/10.1038/nrc3309.

Article  CAS  PubMed  Google Scholar 

Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2006;354(6):567–78. https://doi.org/10.1056/NEJMoa053422.

Article  CAS  PubMed  Google Scholar 

Paliga AA, Onerheim R, Gologan A, Spatz A, Vuong T. EGFR expression in invasive anal carcinoma. J Clin Oncol. 2011;29(4suppl):412–412. https://doi.org/10.1200/jco.2011.29.4_suppl.412.

Article  Google Scholar 

Smaglo BG, Tesfaye A, Halfdanarson TR, et al. Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas. Oncotarget. 2015;6(41):43594–604. https://doi.org/10.18632/oncotarget.6202.

Article  PubMed  PubMed Central  Google Scholar 

Alvarez G, Perry A, Tan BR, Wang HL. Expression of epidermal growth factor receptor in squamous cell carcinomas of the anal canal is independent of gene amplification. Mod Pathol Off J U S Can Acad Pathol Inc. 2006;19(7):942–9. https://doi.org/10.1038/modpathol.3800608.

Article  CAS  Google Scholar 

Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2006;354(6):567–78. https://doi.org/10.1056/NEJMoa053422.

Article  CAS  PubMed  Google Scholar 

In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody1 | clinical cancer research | American Association for cancer research. Accessed May 22. 2026. https://aacrjournals.org/clincancerres/article/6/2/701/287988/In-Vivo-Enhancement-of-Tumor-Radioresponse-by-C225

Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ Published online March. 2021;29:n71. https://doi.org/10.1136/bmj.n71.

Article  Google Scholar 

Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https://doi.org/10.1136/bmj.l4898.

Article  PubMed  Google Scholar 

Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919. https://doi.org/10.1136/bmj.i4919.

Article  PubMed  PubMed Central  Google Scholar 

Margulis AV, Pladevall M, Riera-Guardia N, et al. Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle–Ottawa Scale and the RTI item bank. Clin Epidemiol. 2014;6:359–68. https://doi.org/10.2147/CLEP.S66677.

Article  PubMed  PubMed Central  Google Scholar 

Feliu J, Garcia-Carbonero R, Capdevila J, et al. VITAL phase 2 study: Upfront 5‐fluorouracil, mitomycin‐C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09‐02). Cancer Med. 2019;9(3):1008–16. https://doi.org/10.1002/cam4.2722.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garg MK, Zhao F, Sparano JA, et al. Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group Trial (E3205). J Clin Oncol. 2017;35(7):718–26. https://doi.org/10.1200/JCO.2016.69.1667.

Article  PubMed  PubMed Central  Google Scholar 

Kim DW, Byer J, Kothari N, Mahipal A, Chang YD, Kim RD. EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience. Oncology. 2017;92(4):190–6. https://doi.org/10.1159/000452766.

Article  CAS  PubMed  Google Scholar 

Leon O, Guren MG, Radu C, Gunnlaugsson A, Johnsson A. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer. Eur J Cancer. 2015;51(18):2740–6. https://doi.org/10.1016/j.ejca.2015.08.029.

Article  CAS  PubMed  Google Scholar 

Lonardi S, Prete AA, Morano F, et al. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study. J Immunother Cancer. 2021;9(11):e002996. https://doi.org/10.1136/jitc-2021-002996.

Article  PubMed  PubMed Central  Google Scholar 

Lukan N, Ströbel P, Willer A, et al. Cetuximab-Based Treatment of Metastatic Anal Cancer: Correlation of Response with KRAS Mutational Status. Oncology. 2009;77(5):293–9. https://doi.org/10.1159/000259615.

Article  CAS  PubMed  Google Scholar 

Rogers JE, Jácome AAA, Ohinata A, et al. Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. Expert Rev Anticancer Ther. 2020;20(10):901–8. https://doi.org/10.1080/14737140.2020.1810573.

Article  CAS  PubMed  Google Scholar 

Rogers JE, Sirisaengtaksin A, Leung M, et al. Hepatic metastasectomy in squamous cell carcinoma of the anal canal: a case series of a curative approach. Cancers. 2023;15(15). https://doi.org/10.3390/cancers15153890.

Sparano JA, Lee JY, Palefsky J, et al. Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. J Clin Oncol. 2017;35(7):727–33. https://doi.org/10.1200/JCO.2016.69.1642.

Article  CAS  PubMed  Google Scholar 

Valery M, Cervantes B, Smolenschi C, et al. Efficacy and tolerance of cetuximab in combination with 5 FU plus irinotecan based chemotherapy in metastatic squamous cell anal carcinoma. Dig Liver Dis. 2023;55(3):407–11. https://doi.org/10.1016/j.dld.2022.08.026.

Article  CAS  PubMed  Google Scholar 

Vendrely V, Lemanski C, Gnep K, et al. Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904). Radiother Oncol. 2019;140:84–9. https://doi.org/10.1016/j.radonc.2019.05.018.

Article  CAS  PubMed  Google Scholar 

Vendrely V, Ronchin P, Minsat M, et al. Panitumumab in combination with chemoradiotherapy for the treatment of locally-advanced anal canal carcinoma: Results of the FFCD 0904 phase II trial. Radiother Oncol. 2023;186:109742. https://doi.org/10.1016/j.radonc.2023.109742.

Article  CAS  PubMed  Google Scholar 

Vermorken JB, Mesia R, Rivera F, et al. Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. N Engl J Med. 2008;359(11):1116–27. https://doi.org/10.1056/NEJMoa0802656.

Article  CAS  PubMed  Google Scholar 

Douillard JY, Oliner KS, Siena S, et al. Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. N Engl J Med. 2013;369(11):1023–34. https://doi.org/10.1056/NEJMoa1305275.

Article